ClinicalTrials.gg
RecruitingNCT07243171Updated Nov 16, 2026

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

A Phase 1/2 interventional study of ecnoglutide tablets and placebo with matching dosage in Overweight and/or Obesity and Weight Management, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 16, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..

Planned enrollment
8th of 10
126 · median 152
Started
2025
with 2 others
Phase 1/2
Only one
of the 10
Registered
4th of 10
by date

Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one is the 8th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 1/2, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., or all of them as a file.
02

Study summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Read the detailed description

In this study, eligible participants will be randomized to receive either oral ecnoglutide tablet or placebo once daily for up to 3 weeks (Cohort C1) or 4 weeks (Cohort C2 or C6), or once weekly for up to 24 weeks (Cohort C3, C4 and C5), including a dose escalation period.

03

Conditions studied

  • Overweight and/or Obesity
  • Weight Management

Keywords

  • ecnoglutide
  • glucagon-like peptide-1 (GLP-1)
  • obesity
  • overweight
  • weight management
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of , with in the range of 24.0 to 35.0 kg/m2 (including the threshold), body weight >60.0 kg for male, and weight >50.0 kg for female;
  2. Self-declaration of body weight change \<5% within 3 months prior to informed consent ;

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome;
  2. Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows TI-RADS≥ class 3), thyroid cancer, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc.
  3. Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to acute stroke, acute coronary syndrome, heart failure, arrhythmia, etc.
  4. Diagnosis of severe gastrointestinal diseases, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, diabetic gastroparesis, diabetic diarrhea, clinical gastric emptying abnormalities (such as pyloric obstruction), etc.
  5. History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period;
  6. ≥6.5% or fasting blood glucose ≥7.0 mmol/L, or OGTT 2-hour blood glucose ≥11.1 mmol/L, at screening;
  7. Clinical laboratory test results with clinical significance
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    oral ecnoglutide C1

    once daily, up-titration every 7 days, dosing for 21 days in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

  • Experimental
    oral ecnoglutide C2

    once daily, up-titration every 7 days, dosing for 28 days in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

  • Experimental
    oral ecnoglutide C3

    once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

  • Experimental
    oral ecnoglutide C4

    once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

  • Experimental
    oral ecnoglutide C5

    once weekly, up-titration every 4 weeks, dosing for 24 weeks in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

  • Experimental
    oral ecnoglutide C6

    once daily, up-titration every 7 days, dosing for 28 days in total

    Drug: ecnoglutide tablets · Drug: placebo with matching dosage

Interventions

  • oral tablets, once daily

  • Drugplacebo with matching dosage

    oral tablets, once daily

  • oral tablets, once weekly

  • Drugplacebo with matching dosage

    oral tablets, once weekly

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: up to day 204

Secondary outcomes

  1. Pharmacokinetics of oral ecnoglutide tablet

    Cmax, Tmax and AUC

    Time frame: up to day 204

  2. Change of body weight from baseline

    Time frame: up to day 204

  3. Change of BMI from baseline

    Time frame: up to day 204

  4. Change of waist circumference from baseline

    Time frame: up to day 204

  5. Change of hip circumference from baseline

    Time frame: up to day 204

  6. Change of neck circumference from baseline

    Time frame: up to day 204

  7. Change of waist/hip ratio from baseline

    Time frame: up to day 204

  8. Change of fasting blood glucose from baseline

    Time frame: up to day 204

  9. Change of fasting insulin from baseline

    Time frame: up to day 204

  10. Change of lipid profile from baseline

    Time frame: up to day 204

Other outcomes

  1. anti-drug antibody

    ADA of ecnolgutide

    Time frame: up to day 204

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Nov 18, 2025
Primary completionEst.
Jan 5, 2027
CompletionEst.
Apr 28, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: ecnoglutide tablets·Drug: placebo with matching dosage. Arms added: oral ecnoglutide C1·oral ecnoglutide C2·oral ecnoglutide C3·oral ecnoglutide C4·oral ecnoglutide C5·and 1 more
All 6

oral ecnoglutide C1 · oral ecnoglutide C2 · oral ecnoglutide C3 · oral ecnoglutide C4 · oral ecnoglutide C5 · oral ecnoglutide C6

; arms removed: oral ecnoglutide dose 1·oral ecnoglutide dose 2·oral ecnoglutide dose 3·oral ecnoglutide dose 4·placebo dose 1·and 1 more
All 6

oral ecnoglutide dose 1 · oral ecnoglutide dose 2 · oral ecnoglutide dose 3 · oral ecnoglutide dose 4 · placebo dose 1 · placebo dose 2

Nov 16, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • Changedother outcomeBefore Immunogenecity of oral ecnoglutide tabletNow anti-drug antibodyTime frame: up to day 204
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Changedother outcomeBefore Immunogenecity of oral ecnoglutide tabletNow anti-drug antibodyTime frame: up to day 204
    Interventions Added Drug: ecnoglutide tablets·Drug: placebo with matching dosage. Arms added: oral ecnoglutide C1·oral ecnoglutide C2·oral ecnoglutide C3·oral ecnoglutide C4·oral ecnoglutide C5·and 1 more
    All 6

    oral ecnoglutide C1 · oral ecnoglutide C2 · oral ecnoglutide C3 · oral ecnoglutide C4 · oral ecnoglutide C5 · oral ecnoglutide C6

    ; arms removed: oral ecnoglutide dose 1·oral ecnoglutide dose 2·oral ecnoglutide dose 3·oral ecnoglutide dose 4·placebo dose 1·and 1 more
    All 6

    oral ecnoglutide dose 1 · oral ecnoglutide dose 2 · oral ecnoglutide dose 3 · oral ecnoglutide dose 4 · placebo dose 1 · placebo dose 2

    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07243171
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Nov 18, 2025
Primary completion
Jan 5, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jintong Li, Dr
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion